Back

Impact of Tafamidis on survival in elderly patients in a real-world setting: insights from the Healthcare European Amyloidosis Registry

29 August 2025 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Improving treatment of transthyretin cardiac amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Antoine Jobbe Duval

Medipole Lyon-Villeurbanne, Villeurbanne (France)

3 More presentations in this session

Presentation thumbnail
Assessing functional capacity in patients with ATTR-CM: the role of CPET and 6MWT
Doctor A. Sheikh (London, GB)
Abstract Slides Video
Presentation thumbnail
Fluid status established by bioimpedance vector analysis (BIVA) at diagnosis of wild-type transthyretin amyloidosis is associated with patient survival
Doctor J. Mansell (London, GB)
Abstract Slides Video
Presentation thumbnail
Novel self-supervised learning outperforms traditional AI in ECG-based transthyretin cardiac amyloidosis detection for earlier diagnosis
Mr D. Mcauliffe (Dublin, IE)
Abstract Slides Video

Access the full session

Session thumbnail
Improving treatment of transthyretin cardiac amyloidosis

The Event

Event poster

ESC Congress 2025

29 August 2025 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Survival in a contemporary, real-world, matched cohort of patients with transthyretin amyloid cardiomyopathy treated vs not treated with tafamidis
thumbnail
Congress Presentation
Natural course and effect of tafamidis treatment in real-life octogenarians with wild-type transthyretin cardiac amyloidosis: an international multi-centre analysis.
thumbnail
Congress Presentation
Tafamidis to treat patients with transthyretin cardiac amyloidosis (ATTR-CM): real-world data from a tertiary centre

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources